Study points to novel epigenetic target for Alzheimer's Disease

November 6, 2018, University of Miami
From left, Karolina J. Janczura, Claes Wahlestedt, M.D., Ph.D., and Claude-Henry Volmar, Ph.D. Credit: University of Miami

A research team at the University of Miami Miller School of Medicine's Center for Therapeutic Innovation (CTI) has identified a novel epigenetic drug target to simultaneously normalize multiple deficits in Alzheimer's disease (AD), the most common form of dementia in the elderly and the sixth leading cause of death in the U.S., according to the Alzheimer's Association.

The study, titled "Inhibition of HDAC3 Reverses Alzheimer's Disease-related Pathologies in vitro and in the 3xTg-AD Mouse Model," was published on November 5 in the Proceedings of the National Academy of Sciences (PNAS). The researchers demonstrated that epigenetic "eraser" enzyme, histone deacetylase 3 (HDAC3) is connected to multiple Alzheimer's disease hallmarks, including beta-amyloid (Aβ), hyperphosphorylated tau and several other aberrant genes.

"Importantly, none of the FDA-approved treatments available to date are efficacious at addressing these hallmarks, let alone multiple hallmarks," said senior author Claes Wahlestedt, M.D., Ph.D., professor of psychiatry and behavioral sciences, associate dean for therapeutic innovation, and director of the Center for Therapeutic Innovation. His laboratory conducted the new study, which was supported by the National Institutes of Health and the State of Florida Department of Health (the Ed and Ethel Moore Alzheimer's Disease Research Program).

Karolina J. Janczura, first author of the study, a Ph.D. candidate at the Center for Therapeutic Innovation and an American Heart Association predoctoral fellowship recipient, stated: "This was an incredibly rewarding experience. We were able to demonstrate that it is possible to re-program neuronal cell gene expression and thereby achieve a very striking reversal of deteriorating memory in our Alzheimer's disease model."

Claude-Henry Volmar, Ph.D., co-corresponding author, director of research laboratory at the Center for Therapeutic Innovation and associate director of Molecular Therapeutics Shared Resource at the Sylvester Comprehensive Cancer Center, added: "We discovered that treatment with RGFP-966, an experimental HDAC3 inhibitor drug, normalizes Alzheimer's-like pathology in multiple cellular and animal models. Considering that the majority of clinical trials focused on traditional AD targets have failed to date, our group focused on the multifactorial aspect of the disease, and we hope our recent discovery will guide the development of AD therapeutics."

"Further support of the potential role of HDAC3 in Alzheimer's in this work comes from the fact that its inhibition in AD patient-derived neurons also resulted in reversal of AD phenotype," Janczura said.

"Interestingly, a novel interaction between the protein tau and HDAC3 was discovered in this project, suggesting a possible role of HDAC3 in other tau-related pathologies in addition to AD," Volmar said.

"Most importantly, this work endorses a multipronged approach to the treatment of AD and supports the broad therapeutic potential of a single epigenetic small molecule, bypassing the need for developing multiple drugs to be used in combination," Wahlestedt said.

Explore further: HDAC3 role in B-cell development

More information: Karolina J. Janczura et al. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1805436115

Related Stories

HDAC3 role in B-cell development

August 4, 2017
Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important ...

Promising novel treatment against Alzheimer disease

September 25, 2018
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug ...

Discovery could explain failed clinical trials for Alzheimer's, and provide a solution

September 19, 2018
Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also identifies a clinically ...

Abnormal brain protein may contribute to Alzheimer's disease development

September 30, 2016
A recently-recognized pathologic protein in the brain may play a larger role in the development of clinical Alzheimer's disease dementia than previously recognized, according to a study by researchers at Rush University Medical ...

Can aspirin treat Alzheimer's?

July 2, 2018
A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological researchers at Rush University Medical Center, who published ...

Experimental therapy restores nerve insulation damaged by disease

February 12, 2018
When the body attacks its own healthy tissues in an autoimmune disease, peripheral nerve damage handicaps people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate.

Recommended for you

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...

Massive study confirms that loneliness increases risk of dementia

October 29, 2018
A new Florida State University College of Medicine study involving data from 12,000 participants collected over 10 years confirms the heavy toll that loneliness can take on your health: It increases your risk of dementia ...

Bioactive compound from the Rhodiola plant improves memory

October 25, 2018
In an ageing society, more people are suffering from memory disorders. The progressive loss of memory severely impairs the quality of life of those affected. So far, no drugs are known to prevent age-related cognitive decline.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.